Key result
Both perindopril and telmisartan significantly reduced blood pressure without causing any significant adverse effects on plasma lipid profiles or blood sugar levels after 24 weeks of treatment (p > 0.05).
Why the study?
Do perindopril and telmisartan have adverse effects on serum lipid profiles and blood sugar levels in patients with systemic hypertension?
Observational (n=200)
Open-label
Non-randomized
No
Do perindopril and telmisartan have adverse effects on serum lipid profiles and blood sugar levels in patients with systemic hypertension?
Answers are grounded in this paper and cite their sources.
Perindopril and telmisartan effectively lower blood pressure without causing adverse metabolic effects on lipid or glucose profiles in patients with systemic hypertension.
Background: This study was designed to compare adverse effects on serum lipid profile and blood sugar level in the treatment with two commonly used drugs perindopril and telmisartan in cases of hypertension. This was an “observational” and “cross-sectional” study. Methods: A total of 100 patients were included in each, Groups A and B. In both groups, half the patients were given perindopril 4 mg OD and half were given telmisartan 40 mg OD for 24 weeks. Total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG), fasting blood sugar (FBS), and postprandial blood sugar (PPBS) level was estimated initially and then at 4 th , 12 th , and 24 th week. Statistical analysis was done using ANOVA. Results: With perindopril initial means of TC, HDL, LDL, TGs, FBS, and PPBS in Groups A and B were 190.32, 49.76, 117.96, 165.04, 84.56, 122.60, and 188.80, 51.64, 118.52, 159.12, 93.92, 133.60, respectively. After 24 weeks, these values were 190.84, 50.68, 118.60, 163.84, 83.48, 120.20, and 190.96, 52.04, 118.28, 157.56, 93.96, 133.68, respectively (p > 0.05). With telmisartan, initial means of TC, HDL, LDL, TG, FBS, and PPBS in both groups were 188.08, 49.76, 118.84, 167.20, 83.72, 120.68, and 188.08, 46.88, 121.96, 167.84, 91.44, 131.72, respectively. After 24 weeks, these values in both groups were 189.36, 49.80, 120.04, 165.96, 82.60, 118.36 and 186.12, 45.28, 121.08, 167.72, 92.76, 129.56 respectively (p > 0.05). Conclusions: It concluded that both perindopril and telmisartan had not any significant adverse effects on plasma lipid profile and blood sugar level in both groups.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2014) conducted an observational in Systemic hypertension (n=200). Perindopril vs. Telmisartan 40 mg to 80 mg once daily was evaluated on Changes in serum lipid profile (TC, HDL, LDL, TG) and blood sugar level (FBS, PPBS) (p=>0.05). Both perindopril and telmisartan significantly reduced blood pressure without causing any significant adverse effects on plasma lipid profiles or blood sugar levels after 24 weeks of treatment (p > 0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: